In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC).
The study enrolled 60 patients, 42 of which had non-clear cell RCC and 18 had sarcomatoid clear cell RCC. The majority of the 42 non-clear cell RCC patients had papillary RCC, and there were patients with chromophobe, unclassified, medullary, translocation, or collecting duct RCC in the study.
Patients were treated with the standard dose of atezolizumab (1200 mg) with bevacizumab (15 mg/kg) intravenously every 3 weeks until progression of their disease. The primary endpoint was overall response rate. Almost 50% of patients had had prior systemic therapy.
Overall response rate in all the patients was 33%. In patients with sarcomatoid clear cell RCC, response rate was over 50%, and in patients with non-clear cell RCC (42 patients), response rate was 26%. Response rates were lowest in patients with chromophobe RCC (10%). Atezolizumab plus bevacizumab was very well tolerated with very few severe adverse events.